News | July 06, 2025
GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
_256_384.jpg)
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Subscribe To Our Newsletter & Stay Updated
